www.turner-white.com Oncology Volume 11, Part 4 11
Advances in the understanding of the pathophysiology of CML and subsequent deployment of
rationally designed, mechanistic-focused therapy
has changed the epidemiology of CML in historic
fashion. The therapeutic options available for CML
continue to improve, and the aspirations of clinical research grow in step. Though treatment-free
remissions are not to be expected in all patients,
our understanding of the conditions which safely
allow for “treatment holidays” is growing, and may
be incorporated into standard therapy in the near
future.72,76 Likewise, combination therapy holds
the promise for potentially eliminating the need for
lifelong therapy.77,78 Since the advent of TKIs, the
incidence of CML has not changed, but as overall
survival improves there is a concordant growth in
prevalence. Key remaining challenges are to continue to improve quality and efficiency of therapy in
a health care economy of limited resources.
1. Nowell PC. Discovery of the Philadelphia chromosome: a
personal perspective. J Clin Invest 2007;117: 2033–5.
2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified
by quinacrine fluorescence and Giemsa staining. Nature
3. Heisterkamp N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic
myelogenous leukemia in mice by the P210bcr/abl gene of
the Philadelphia chromosome. Science 1990;247:824–30.
5. Weinberg RA. The integration of molecular genetics into
cancer management. Cancer 1992;70(Suppl):1653–8.
6. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a
selective inhibitor of the Abl tyrosine kinase on the growth
of Bcr-Abl positive cells. Nat Med 1996;2:561–6.
7. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety
of a specific inhibitor of the BCR-ABL tyrosine kinase in
chronic myeloid leukemia. N Engl J Med 2001;3441031–7.
8. Yoshida K, Komatsu K, Wang HG, Kufe D. c-Abl tyrosine
kinase regulates the human Rad9 checkpoint protein in response to DNA damage. Mol Cell Biol 2002; 22:3292–300.
9. Ziemnicka-Kotula D, Xu J, Gu H, et al. Identification of a
candidate human spectrin Src homology 3 domain-binding
protein suggests a general mechanism of association of
tyrosine kinases with the spectrin-based membrane skeleton. J Biol Chem 1998;273:13681–92.
10. Yuan ZM, Shioya H, Ishiko T, et al. p73 is regulated by
tyrosine kinase c-Abl in the apoptotic response to DNA
damage. Nature 1999;399:814–7.
11. Voncken JW, Kaartinen V, Groffen J, Heisterkamp N. Bcr/
Abl associated leukemogenesis in bcr null mutant mice.
12. Chan LC, Karhi KK, Rayter SI, et al. A novel abl protein
expressed in Philadelphia chromosome positive acute
lymphoblastic leukaemia. Nature 1987;325:635–7.
13. van Etten RA. Disease progression in a murine model of
bcr/abl leukemogenesis. Leuk Lymphoma 1993;11 Suppl
14. Zhao R, Follows GA, Beer PA, et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N
Engl J Med 2008;359:2778–89.
15. Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008;8:341–50.
16. Calabretta B, Perrotti D. The biology of CML blast crisis.
17. Gaiger A, Henn T, Hörth E, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic
myeloid leukemia precedes disease progression. Blood
18. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ.
Alterations in the p53 gene and the clonal evolution of the
blast crisis of chronic myelocytic leukemia. Proc Natl Acad
19. Tanaka K, Takechi M, Hong J, C. et al. 9;22 translocation
and bcr rearrangements in chronic myelocytic leukemia
patients among atomic bomb survivors. J Radiat Res
20. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic
myeloid leukemia in the era of tyrosine kinase inhibitor
therapy. Cancer 2012;118:3123–7.
BOARD REVIEW QUESTIONS
Test your knowledge of this topic.
Go to www.turner-white.com and select Oncology
from the drop-down menu of specialties.